Overview on Diagnosis and Treatment of Prostate Cancer
Keywords:
Adverse Effect, Cancer, Prostate, Tumor, TreatmentAbstract
The prostate cancer is leading reason cancer diagnosis for males in the United States, with over 160 300 fresh cases diagnosed each year. The prostate cancer is indeed the third-leading reason of cancer mortality in males, despite its typically indolent course. Tissue biopsy is still the gold average for diagnosing prostate cancer when it is suspected. However, better risk stratification and improvements in mri scans and functional imaging, and the development of biomarkers, have made illness diagnosis and characterization more accurate. Men who have been diagnosed with breast cancer now have a variety of treatment choices. Surgery and radiation are still curative therapies for localized illness, but they include side effects including urinary problems and sexual dysfunction, which may lower quality of life. Chemotherapy as a first-line treatment for metastatic illness now seems to improve survival when compared to hormone therapy alone. In men suffering metastatic prostate cancer who are resistant to conventional hormone treatment, new vaccinations, hormonal therapies, and bone-targeting medicines have shown effectiveness. Advances in prostate cancer detection and treatment have enhanced doctors' capacity to stratify patients into risk and suggest therapy depending on cancer prediction and patient preference. When compared to androgen deprivation therapy, chemotherapy may help patients live longer. In men suffering metastatic prostate cancer who are resistant to conventional hormone treatment, abiraterone, enzalutamide, as well as other medicines may help.
Downloads
References
M. Daniyal, Z. A. Siddiqui, M. Akram, H. M. Asif, S. Sultana, and A. Khan, “Epidemiology, etiology, diagnosis and treatment of prostate cancer,” Asian Pacific Journal of Cancer Prevention. 2014, doi: 10.7314/APJCP.2014.15.22.9575.
S. Sharma, M. S. Hussain, N. B. Agarwal, D. Bhurani, M. A. Khan, and M. A. Ahmad Ansari, “Efficacy of sirolimus for treatment of autoimmune lymphoproliferative syndrome: a systematic review of open label clinical studies,” Expert Opinion on Orphan Drugs. 2021, doi: 10.1080/21678707.2021.1970523.
A. Gasnier and N. Parvizi, “Updates on the diagnosis and treatment of prostate cancer,” British Journal of Radiology. 2017, doi: 10.1259/bjr.20170180.
S. Hussain, A. Singh, A. Habib, M. S. Hussain, and A. K. Najmi, “Comment on: ‘Cost Effectiveness of Dialysis Modalities: A Systematic Review of Economic Evaluations,’” Applied Health Economics and Health Policy. 2019, doi: 10.1007/s40258-019-00485-4.
S. Stojkovikj, S. Oklevski, O. P. Jasuja, and M. Najdoski,
“Visualization of latent fingermarks on thermal paper: A new method based on nitrogen dioxide treatment,” Forensic Chem., 2020, doi: 10.1016/j.forc.2019.100196.
B. Gupta and P. Ahluwalia, “Need for a central survey based registry-for effective conduct of survey-based medical research,” Indian Journal of Anaesthesia. 2021, doi: 10.4103/ija.ija_275_21.
P. S. Matreja, J. Kaur, and L. Yadav, “Acceptability of the use of crossword puzzles as an assessment method in pharmacology,” J. Adv. Med. Educ. Prof., 2021, doi: 10.30476/jamp.2021.90517.1413.
Y. Qu and W. Huang, “Effects of microRNA-210 on the diagnosis and treatment of prostate cancer,” Mol. Med. Rep., 2018, doi: 10.3892/mmr.2018.9105.
S. Agarwal, A. Agarwal, and S. Chandak, “Role of placenta accreta index in prediction of morbidly adherent placenta: A reliability study,” Ultrasound, 2021, doi: 10.1177/1742271X20959742.
R. Jain, R. P. S. Tomar, V. K. Singh, V. Rastogi, and R. Rastogi, “Study of association between metabolic syndrome and acute myocardial infarction,” J. Int. Med. Sci. Acad., 2021.
G. Di Pietro, G. Chornokur, N. B. Kumar, C. Davis, and J. Y. Park, “Racial differences in the diagnosis and treatment of prostate cancer,” International Neurourology Journal. 2016, doi: 10.5213/inj.1632722.361.
A. Agarwal, “Neuralgic Amyotrophy of Posterior Interosseous Nerve: A Cryptic and Crucial Entity,” Journal of Ultrasound in Medicine. 2022, doi: 10.1002/jum.15721.
B. L. Kinlock et al., “Racial disparity in time between first diagnosis and initial treatment of prostate cancer,” Cancer Control, 2016, doi: 10.1177/107327481602300108.
L. M.S. and T. H.-J., “The diagnosis and treatment of prostate cancer: A review,” JAMA - J. Am. Med. Assoc., 2017.
J. Hernandez and I. M. Thompson, “Diagnosis and treatment of prostate cancer,” Medical Clinics of North America. 2004, doi: 10.1016/S0025-7125(03)00144-5.
R. Skiba, T. Syryło, and T. Ząbkowski, “Diagnosis and treatment of prostate cancer in elderly men,” Pediatr. i Med. Rodz., 2015, doi: 10.15557/pimr.2015.0003.
P. Bagnall, “Diagnosis and treatment of prostate cancer,” Nursing Times. 2014.
J. Graham, M. Baker, F. Macbeth, and V. Titshall, “Diagnosis and treatment of prostate cancer: Summary of NICE guidance,” BMJ. 2008, doi: 10.1136/bmj.39498.525706.AD.
B. Ahn, K. Park, H. Lee, and J. Kim, “A survey of robotic technologies for diagnosis and treatment of prostate cancer,” J. Inst. Control. Robot. Syst., 2010, doi: 10.5302/J.ICROS.2010.16.9.852.
S. M. Inder et al., “Impact of rapid access prostate cancer clinics in the diagnosis and treatment of prostate cancer,” BJU Int., 2017.
